Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Vafidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORYZON Reports Q3 2024 Financial Results And Update
    ORYZON Reports Q3 2024 Financial Results And Update

    24 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/10/24/2968961/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-September-30-2024.html

    GLOBENEWSWIRE
    24 Oct 2024
    Share Share
    Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data
    Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951325/0/en/ORYZON-Presents-the-Final-Data-From-PORTICO-a-Global-Phase-IIb-Vafidemstat-Trial-in-Borderline-Personality-Disorder-BPD-at-the-European-College-of-Neuropsychopharmacology-ECNP-Cong.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality
    ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944681/0/en/ORYZON-Receives-Intention-to-Grant-Communication-for-Patent-Relating-to-the-Use-of-Vafidemstat-in-Borderline-Personality-Disorder.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share
    ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant
    ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2939652/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat-with-Additional-Decision-to-Grant-Communications.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    ORYZON To Receive Two Important Patents For Vafidemstat In Japan
    ORYZON To Receive Two Important Patents For Vafidemstat In Japan

    08 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/08/2909570/0/en/ORYZON-Receives-Decision-to-grant-for-Two-Important-Patents-for-Vafidemstat-in-Japan.html

    GLOBENEWSWIRE
    08 Jul 2024
    Share Share
    ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial
    ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial

    26 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/26/2904462/0/en/ORYZON-Announces-Presentation-of-Final-Data-From-PORTICO-Vafidemstat-s-Global-Phase-IIb-Trial-in-Borderline-Personality-Disorder-at-the-37th-ECNP-Annual-Conference.html

    GLOBENEWSWIRE
    26 Jun 2024
    Share Share